Intuitive Surgical reports upbeat quarterly earnings on strong demand for surgical robots

Intuitive Surgical (ISRG.O) surpassed second-quarter profit and revenue estimates, reporting adjusted EPS of $2.19 on $2.44 billion in revenue, driven by robust demand for its da Vinci surgical robots which saw worldwide procedure volumes increase by approximately 17% year-over-year. The medical device maker subsequently raised its 2025 outlook for global da Vinci-assisted procedures to 15.5%-17% growth and adjusted gross profit margin to 66%-67%. Despite the strong performance and updated guidance, shares of Intuitive Surgical declined 1.5% in after-hours trading.

Analysis

Intuitive Surgical (ISRG) delivered a strong second-quarter performance, exceeding analyst expectations on both revenue and profit. The company reported adjusted earnings of $2.19 per share against a $1.92 consensus estimate, and revenue of $2.44 billion, surpassing the projected $2.35 billion. This outperformance was primarily driven by a significant 17% year-over-year increase in worldwide da Vinci procedure volumes, indicating sustained demand for minimally invasive surgeries as hospitals address procedural backlogs. Management signaled confidence by raising its 2025 guidance, lifting the forecast for global da Vinci procedure growth to a range of 15.5% to 17% and increasing the adjusted gross profit margin outlook to between 66% and 67%. The margin guidance improvement was also aided by a reduced anticipated impact from tariffs. Despite these robust results and positive revisions, the company's shares declined 1.5% in after-hours trading, suggesting that market expectations may have been even higher or that investors engaged in a 'sell the news' reaction.

Key Decisions for Investors

• The negative 1.5% after-hours stock reaction despite a significant earnings and guidance beat suggests that high expectations are already priced into the stock, warranting caution for initiating new long positions.
• Investors should view the 17% procedure volume growth and raised gross margin forecast as confirmation of strong underlying business fundamentals, potentially justifying a 'buy on weakness' approach for those with a long-term thesis.
• Monitor future earnings reports closely to ensure procedure growth and margin execution meet the newly elevated guidance, as any failure to do so could trigger a significant repricing given the market's high expectations.